Investigational drug · Phase 2
BI 836880
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
8
Any phase or sponsor naming "BI 836880"
First trial start
2019
Mar 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 836880", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasm Metastasis
- Advanced Tumors
- Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 836880" as an intervention, largest first.
Boehringer IngelheimBoehringer Ingelheim
NCT03468426 · 252 participants · Start Jul 5, 2018 · Primary completion Jul 31, 2024
Drug: BI 836880; Ezabenlimab · For: Non-squamous, Non-Small-Cell Lung Cancer; Neoplasms
Sites: Birmingham, Alabama; Beverly Hills, California; Atlanta, Georgia · 43 sites in all
- Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid TumoursPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03697304 · 211 participants · Start Mar 19, 2019 · Primary completion Dec 3, 2024
Drug: Ezabenlimab; BI 754111 and 1 more · For: Neoplasm Metastasis; Advanced Tumors; Metastatic Solid Tumors
Sites: La Jolla, California; Fort Myers, Florida; St. Petersburg, Florida · 17 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05249426 · 48 participants · Start Apr 12, 2022 · Primary completion Jul 15, 2024
Drug: BI 765063; Ezabenlimab and 2 more · For: Head and Neck Squamous Cell Carcinoma (HNSCC)
Sites: Los Angeles, California; Dijon, France; Lyon, France · 25 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03861234 · 43 participants · Start Jun 27, 2019 · Primary completion Nov 1, 2023
Drug: BI 836880 · For: Wet Macular Degeneration
Sites: Phoenix, Arizona; New York, New York; Eugene, Oregon · 14 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02674152 · 29 participants · Start Jan 5, 2016 · Primary completion Sep 12, 2018
Drug: BI 836880 · For: Neoplasms
Sites: Paris, France; Augsburg, Germany; Freiburg im Breisgau, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT02689505 · 24 participants · Start Apr 4, 2016 · Primary completion Jul 31, 2019
Drug: BI 836880 · For: Neoplasms
Sites: Dijon, France; Barcelona, Spain
Boehringer IngelheimBoehringer Ingelheim
NCT03972150 · 21 participants · Start Jun 12, 2019 · Primary completion Oct 27, 2020
Drug: BI 836880; BI 754091 · For: Neoplasms
Sites: Shizuoka, Sunto-gun, Japan; Tokyo, Chuo-ku, Japan
Boehringer IngelheimBoehringer Ingelheim
NCT04499352 · 0 participants · Start Sep 14, 2020 · Primary completion Oct 19, 2020
Drug: BI 754091; BI 836880 · For: Anal Canal Squamous Cell Carcinoma
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.
Shirian JD, Shukla P, Singh RP · Eye (Lond) 2025
- Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor.
Keller S, Kunz U, Schmid U, et al. · J Transl Med 2024
- Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models.
Lam RCT, Hui CWC, Wong CH, et al. · Invest New Drugs 2023
- Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Yamamoto N, Koyama T, Shimizu T, et al. · Cancer Chemother Pharmacol 2023
- Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
Hofmann I, Baum A, Hofmann MH, et al. · J Pharmacol Exp Ther 2023
- Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.
Le Tourneau C, Becker H, Claus R, et al. · ESMO Open 2022
Also in development for Neoplasm Metastasis
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- TersolisibLY4064809, STX-478Phase 33 trials
Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- VepugratinibLY3866288Phase 32 trials
Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- BI 754111Phase 21 trial
Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- IPN60350Phase 21 trial
Ipsen · Neoplasms, Neoplasm Metastasis, Neoplastic Processes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.